Importantly, while wild type BRAF does not bind to MST1, the oncogenic mutant BRAFV600E can bind to this tumour suppressor, which could conceivably shut down the anti-oncogenic signal mediated by MST1/2 in several cancer types [96]. This evidence concerns the gene MST1 and neoplasm.